Summary of Purpose
Personalized therapy as prophylaxis in ischemic stroke patients is not yet an option. From patients with ischemic heart disease, we know that patients with in vitro high on treatment platelet reactivity (HTPR) have an increased risk of stent thrombosis following per-cutaneous coronary intervention. Other studies have shown association of CYP2C19 genotypes with different responses to the anti platelet drug...Read More →
The following dates are available for this trial. Trial information last updated on 20 December 2017.
|1 Nov 2015||21 Aug 2017||30 Jul 2017||30 Jul 2017||1 Dec 2017||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|